Tirzepatide: Mounjaro & Zepbound Complete Guide

What Is Tirzepatide?

Tirzepatide is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist developed by Eli Lilly. It belongs to a novel class sometimes called "twincretins" — it activates two distinct incretin hormone receptor types simultaneously, unlike semaglutide which acts only on GLP-1 receptors.

GIP and GLP-1 are both incretin hormones released from the gut in response to food intake. Together, they stimulate insulin release, suppress glucagon, and regulate appetite and energy balance. Tirzepatide's dual action is believed to produce more pronounced glycemic control and weight loss effects than GLP-1 receptor agonism alone — a hypothesis supported by large clinical trial results.

Tirzepatide is a once-weekly subcutaneous injection. It is available in two FDA-approved brand-name products with different indications.

FDA-Approved Products Containing Tirzepatide

Both products are manufactured by Eli Lilly and are prescription-only. They contain the same active ingredient at the same doses but have different FDA-approved indications.

Dual Mechanism: GIP + GLP-1

Tirzepatide's dual mechanism is its defining characteristic. Understanding how each receptor system contributes helps explain the clinical results:

• GLP-1 receptor activation: Stimulates glucose-dependent insulin secretion, suppresses glucagon, slows gastric emptying, and reduces appetite by acting on hypothalamic appetite centers.
• GIP receptor activation: GIP stimulates insulin secretion in a glucose-dependent manner and may also enhance the effects of GLP-1 receptor activation. GIP receptors are expressed in adipose tissue, where they may influence energy storage and fatty acid metabolism. The exact contribution of GIP agonism to tirzepatide's overall clinical effect is an active area of research.

The SURMOUNT weight management trials showed greater average weight loss with tirzepatide than was seen in the STEP trials with semaglutide 2.4 mg — though these were separate studies with different populations. Individual results vary, and choosing between tirzepatide and semaglutide products is a clinical decision.

Differences Between Mounjaro and Zepbound

Mounjaro and Zepbound contain the same active ingredient (tirzepatide) at the same doses. The primary difference is their FDA-approved indication and the resulting insurance coverage implications:

• Mounjaro: Indicated for type 2 diabetes. More commonly covered by commercial insurance for this indication. May also be prescribed off-label for weight management.
• Zepbound: Indicated for chronic weight management. Insurance coverage is less consistent. Eli Lilly has offered self-pay vial options for Zepbound that may be available to eligible patients.

Which product a clinician prescribes depends on your medical situation, diagnosis, insurance coverage, and clinical factors. See our Mounjaro guide and Zepbound guide for more detail on each.

Compounded Tirzepatide: What to Know

Compounded tirzepatide is a preparation made by licensed compounding pharmacies using bulk tirzepatide API. Like compounded semaglutide, it is distinct from FDA-approved Mounjaro and Zepbound in important ways:

• Compounded tirzepatide is not FDA-approved and has not undergone clinical trial review or manufacturing oversight equivalent to FDA-approved products.
• It is not a generic of Mounjaro or Zepbound. No FDA-approved generic tirzepatide exists.
• Its legal status has depended on FDA drug shortage list status for tirzepatide products, which has changed over time.
• The FDA has issued warnings about compounded GLP-1 products, including tirzepatide, related to dosing errors and illegal marketing.

See our compounded GLP-1 guide and tirzepatide cost guide for more information.